NCT01194219View on ClinicalTrials.gov

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL

Enrollment

844

Participants

Timeline

Start Date

September 9, 2010

Primary Completion Date

February 23, 2012

Study Completion Date

November 22, 2016

Conditions

Plaque Psoriasis

Interventions

DRUG

Apremilast

DRUG

Placebo

Identical matching placebo

DRUG

Topical treatments or phototherapy

At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.